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Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired hetero-
geneous disorder of immune origin affecting the peripheral nerves, causing motor weakness and 
sensory symptoms and signs. The precise pathophysiology of CIDP remains uncertain although 
B and T cell mechanisms are believed to be implicated. Intravenous immunoglobulins (IVIg) 
have been shown in a number of trials to be an effective treatment for CIDP. IVIg is thought 
to exert its immunomodulatory effects by affecting several components of the immune system 
including B-cells, T-cells, macrophages and complement. This article provides an overview of 
the pathogenesis of CIDP and of its treatment with IVIg.
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Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired heteroge-
neous disorder affecting peripheral nerves caused by a demyelinating process, producing 
sensory loss and positive sensory symptoms as well as motor weakness. Its prevalence 
may be as high as 9 per 100,000.1 Its reported incidence is variable, with recent analyses 
suggesting figures between 0.50 and 1.60 per 100,000 per year.1,2 In its typical form, 
the disorder is symmetric and involves both proximal and distal limb regions. There 
are rarer atypical forms, also known as Lewis-Sumner syndrome, which can produce 
predominantly uni- or multifocal as well as distal involvement.3 Diagnosis relies on 
clinical features, and also mainly on electrophysiology, which allows demonstration of 
a demyelinating process, producing slowing of nerve conductions in various segments 
as well as conduction block.4 Cerebrospinal fluid protein level is raised in the majority 
of cases, and peripheral nerve histology, may be useful in demonstrating a demyelinat-
ing process with inflammatory features.4 Magnetic resonance imaging (MRI) can show 
thickened hyperintense nerve roots, trunks or plexi.4 As we will see in this article, the 
pathogenesis of CIDP is inflammatory, most probably autoimmune, involving both 
T cells and antibodies. Intravenous immunoglobulins (IVIg) as well as steroids and 
plasma exchanges have been shown to be effective treatments for CIDP.4 The efficacy 
of IVIg in CIDP has been shown in different randomized controlled trials.4
Pathophysiology
The clinical similarity of chronic inflammatory demyelinating polyneuropathy to Guillain-
Barré Syndrome, its histologic resemblance to experimental autoimmune neuritis and 
its response to immunosuppressive therapy, all suggest an autoimmune pathogenesis. Biologics: Targets & Therapy 2010:4 46
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Experimental autoimmune neuritis can be induced in rodent 
models by immunization with peripheral nerve myelin or 
myelin proteins emulsified with Freund’s adjuvant.5,6 A similar 
disease can be induced in Lewis rats with purified Protein 2 
(P2), Protein 0 (P0) glycoprotein, or Peripheral Myelin Protein 
22 (PMP22).7–9 The models most studied have been acute, 
although, some animals develop a chronic relapsing illness 
with histological appearances resembling CIDP.10–13
Currently, neither the target antigen nor the cell popula-
tion responsible for the pathogenesis of CIDP have been 
identified. Myelin proteins, mainly P0, P2 and PMP22, have 
been investigated because of their abilities to induce EAN in 
animals.9,14 Recent studies have focused on P0 because it is 
the most abundant peripheral nerve myelin protein and can 
induce EAN. In the study of Yan et al western immunoblot 
technique identified antibodies to P0 in six of 21 CIDP 
patients who were responsive to plasma exchange and only 
in one of 15 controls.15 Allen and colleagues also found 
antibodies to P0-like bands by immunoblot in eight of 32 
patients with CIDP and none in 30 normal controls.16 How-
ever, Sanvito et al did not find a significant difference in the 
proportion of subjects with IgG anti-P0 peptides in patients 
with CIDP compared with controls, although individual 
subjects with CIDP had high titers. In this study there was a 
higher proportion of untreated CIDP patients compared with 
healthy controls (4/18 vs 0/32) with IgG antibodies to P2.17 
The detection of antibodies to P0 and other myelin protein 
is likely to be dependent on their conformation, which may 
only be found on the intact protein in its natural membrane 
environment. Studies looking for antibodies to gangliosides 
have been unrewarding in CIDP in contrast to MMN.18
Antibodies are not believed to, by themselves, produce 
demyelination as they are unable to penetrate the blood-nerve 
barrier unless it is already permeable. There is evidence that a 
T-cell response is also involved. Systemic and local activation 
of T-cells has been demonstrated in CIDP19–21 and in one study 
circulating T-cell responses were detected to a P0 peptide in 3 of 
13 cases.22 Furthermore, the antibodies to P0 glycoprotein in Yan 
and colleagues’ study were mainly IgG 1, a subclass that implies 
T-cell activation.15 It is likely that both B and T-cell mechanisms 
are involved. More research is needed to establish the target of 
the T-cell response and whether other cell populations, like NK 
and T-cells are relevant to the pathogenesis of CIDP.
Treatment with intravenous 
immunoglobulins: rationale, 
evidence-base and practice
The treatment of CIDP is based on the notion that the patho-
genesis is likely to be immune mediated. The three proven 
treatments from randomized controlled trials for CIDP are 
corticosteroids, plasma exchange and intravenous immuno-
globulin.23–27 Immunosuppresive therapies like methotrexate, 
azathioprine, cyclophosphamide, cyclosporin A, mycophe-
nolate and alemtuzumab have been used anecdotally. In 
addition, immunomodulatory agents such as beta interferon 
have had reports of beneficial effect although a randomized 
controlled trial failed to confirm this benefit.28,29
Intravenous immunoglobulin (IVIg) consists of IgG 
obtained from the pools of plasma of several thousand 
healthy blood donors. The mechanism of action of IVIg is 
complex; it modulates the expression and function of Fc 
receptors, interferes with the activation of complement and 
the cytokine network, regulates of cell growth and neutralize 
of circulating auto-antibodies.30 IVIg was first shown to be 
beneficial in idiopathic thrombocytopenic purpura more than 
25 years ago.31 Since then, IVIg has been used in a num-
ber of autoimmune and inflammatory diseases. Although 
the presence of natural antibodies capable of recognizing 
foreign antigens could plausibly explain the role of IVIg in 
IgG replacement therapy, the precise mechanism of action 
by which IVIg exerts its immunomodulatory effects is not 
clearly understood. In inflammatory neuropathies there are 
several proposed pathophysiological mechanisms. Anti-
idiotype antibodies are likely to be involved in the thera-
peutic effects of IVIg and other B-cell mediated effects of 
IVIg include inhibition of antibody production,32 inhibition 
of B-cell differentiation,33 inhibition of production of inter-
leukin-6 and tumour necrosis factor-α,34 induction of B-cell 
apoptosis,35 downregulation of specific auto-reactive B-cells 
and regulation of B-cell subsets expressing CD5,36 thereby 
suppressing the auto-antibody producing CD20+ B1 cells. 
IVIg is thought to potentially accelerate the breakdown of 
endogenous IgG which may be mediating the autoimmune 
response.37 IVIg has also been shown in experimental ani-
mals to modulate B-cell migration from bone marrow to sec-
ondary lymphoid organs.38 In animal models of experimental 
autoimmune encephalomyelitis and autoimmune uveitis, 
IVIg is thought to reduce the production of interleukin-2 
and interferon-γ by T-cells,39,40 preventing the development 
of disease. This is also thought to be one of the major effector 
mechanisms in the treatment of CIDP. The anti-inflamma-
tory activity of IVIg is at least partly mediated by its ability 
to prevent the formation of membrane attack complex and 
subsequent tissue destruction. Antibodies against several 
components of the classical complement pathway have 
been identified in IVIg.41–43 IVIg-mediated inhibition of 
macrophage function may furthermore reduce the phago-
cytosis of antigen-presenting cells and antibody-mediated Biologics: Targets & Therapy 2010:4 47
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cellular cytotoxicity, thus inhibiting macrophage-mediated 
demyelination.44
In CIDP, Vermeulen et al initially reported treating 17 
patients with infusions of fresh-frozen plasma which contains 
IVIg. There was improvement in 13 patients.45 Subsequent 
open studies of IVIg reported benefit ranging from nine 
out of nine patients46 and 32 of 52 patients,47 to 3 of 15.48 
The first double-blind, randomized, placebo controlled trial 
was a cross-over of trial of seven patients who were known 
responders to IVIg; all seven patients improved on IVIg but 
none improved on placebo.27 Another study by the same 
investigators did not show a difference in response between 
patients who received IVIg and those on placebo.49 These 
varying results indicated the need for further trials. A ran-
domized, double-blind, placebo-controlled, cross-over trial 
found a significant improvement in disability scores in 19 of 
30 (63%) patients treated with IVIg.25 In a large randomized 
trial of 53 patients (30 IVIg vs 23 placebo), 11 in the IVIg 
group and 2 patients improved in a functional disability scale 
(P = 0.019).26 There have also been trials comparing IVIg with 
corticosteroids and plasma exchange, the other two proven 
treatments in CIDP. A randomized, double-blind, crossover 
trial of 32 patients comparing IVIg with prednisolone (oral 
prednisolone tapering from 60 mg to 10 mg daily over 6 
weeks) showed significant improvement in disability in 
patients receiving either treatment.50 In the cross over trial of 
IVIg versus plasma exchange, patients were randomized to 
receive IVIg (0.4 g/kg once a week for 3 weeks, then 0.2 g/kg 
once a week for the next 3 weeks) or plasma exchange twice 
weekly for 3 weeks then once weekly for another 3 weeks. 
The study was a unblinded and analysis was not intention to 
treat, nonetheless there was no difference between the effi-
cacy of IVIg and plasma exchange; both treatments resulting 
in significant improvement.51
Meta-analysis showed significant short-term reduction in 
disability and improvement in strength with IVIG but there 
was lack of evidence about the long-term benefit of IVIg.52 
A recent randomized, double-blind, placebo-controlled, 
response-conditional crossover trial of 117 patients with 
CIDP confirmed the long-term use of IVIg. Patients were 
treated with an initial loading dose of 2 g/kg10% capry-
late-chromatography purified immune globulin intravenous 
(IGIV-C), followed by a maintenance dose of 1 g/kg every 3 
weeks for 24 weeks. After these 24 weeks, only patients who 
improved during the first study period were re-randomized 
for an extension phase of another 24 weeks. In first period, 
32 of 59 (54%) patients treated with IGIV-C and 12 of 58 
(21%) patients who received placebo improved in adjusted 
inflammatory neuropathy cause and treatment (INCAT) 
disability score (P = 0⋅0002). Similar results were obtained in 
the crossover period. During the extension phase, participants 
who continued to receive IGIV-C took a longer time before 
they relapsed (a worsening of adjusted INCAT disability score 
by 1 point or more from baseline value of the extension) than 
did patients treated with placebo (P = 0⋅011).53
The standard initiating dose of IVIg for treating CIDP is 
2 g/kg body weight over 5 days. The effect is short-lived and 
patients usually require repeated infusions. A retrospective 
study of 15 patients showed considerable dose and treat-
ment frequency variability, in individual patients. In this 
study, IVIg dose reductions were achieved in all patients 
(mean: 63.3%, range: 42.4% to 88%),54 raising the ques-
tion about the need for prospective dose-comparative trials 
in CIDP, as have been performed in myasthenia gravis.55 
Recent randomized controlled trials in CIDP have also 
found that patients did not require as much IVIg as they 
were receiving. In the RMC trial of methotrexate for CIDP, 
14 of 32 (44%) of patients on placebo were able to reduce 
their IVIg or corticosteroids by more than 20%.56 Similarly, 
in a study of the efficacy of interferon beta-1a in patients 
with CIDP, 8 of 17 (47%) patients in the placebo group who 
completed the study did not restart IVIg therapy after IVIg 
was withdrawn.57 Intravenous immunoglobulin is expensive; 
a cost-of-illness study of inflammatory neuropathies showed 
that the average annual cost per patient for those on IVIg 
was £17,107 and those not requiring IVIg, £59 only.58 It 
is therefore important that clinicians ensure that patients 
are only given the minimum dose of IVIg they require. 
However, it remains unclear whether continuous treatment 
may have long-term favorable effects and maintaining 
patients on lower doses of IVIg may as a result in further 
deterioration so that dosing should be directed at maintain-
ing maximal function.59 CIDP patients on IVIg often receive 
their infusions as in-patients, which adds to the drug costs. 
Subcutaneous immunoglobulins is an alternative which can 
be self-administered by patients at home. An observational 
study of 1500 infusions in primary immunodeficiency 
diseases showed that patients tolerate it well.60,61 There 
have been few reports of its successful use in CIDP.62,63 
Controlled studies of subcutaneous immunoglobulins are 
needed to establish appropriate dose and measure quality 
of life. An economic study comparing the intravenous and 
subcutaneous routes is also necessary.
Conclusion
CIDP is a heterogeneous disorder of complex autoimmune 
basis which has been found to be treatment responsive in 
approximately 80% of cases.64 Intravenous immunoglobulins Biologics: Targets & Therapy 2010:4 48
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represents a safe and effective treatment for CIDP. However, 
about a third of patients do not respond to IVIg. Furthermore, 
cost and availability are also major issues that affect its use. The 
reasons for IVIg unresponsiveness remain unclear although 
genetic factors may play a role.65 Treatment options in such 
unresponsive remain steroid therapy and plasma exchanges, 
although these are less well tolerated. Further research may shed 
light on the important persistent questions regarding long-term 
use of IVIg for CIDP, and this will require consideration of 
alternatives as well as, of more adequate and evidence-based 
use of this highly effective but costly treatment.
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